Oxford BioTherapeutics (OBT), a clinical-stage oncology firm, has announced a long-term partnership with Roche ...

PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has reported its financial results for the year ending December ...

Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...

An experimental drug has shown promise in preventing Alzheimer’s for people at higher risk of developing the disease.

Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya ...

Ben Greenberg, and Monson.) It’s rare to see antibodies capable of protecting neurons, said Greenberg, a neurologist and the vice chair of clinical and translation research at UT Southwestern ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...

Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...

(NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative ...

The treatment was approved by China’s National Medical Products Administration (NMPA) and is China's first, and the world’s ...

Pharmaceuticals announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients ...